Maribavir (ViroPharma)

Current Opinion in Investigational Drugs

Volumn 5, Issue 8, 2004, Pages 898-906

  Lu, Henry ^a   Sun, Thomas ^a  

^a RIGEL PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; BENZIMIDAVIR; BENZIMIDAZOLE DERIVATIVE; NUCLEIC ACID SYNTHESIS INHIBITOR; RIBONUCLEOSIDE;

ANIMAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CYTOMEGALIC INCLUSION BODY DISEASE; HUMAN; PATENT; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTIVIRAL AGENTS; BENZIMIDAZOLES; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; CYTOMEGALOVIRUS INFECTIONS; HUMANS; NUCLEIC ACID SYNTHESIS INHIBITORS; PATENTS; RANDOMIZED CONTROLLED TRIALS; RIBONUCLEOSIDES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 16644364829     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (52)

1. 185301 Synthesis and antiviral evaluation of several 5'-modified derivatives of 2,5,6-trichloro-1-(β-D-ribofuranosyl)benzimidazole (TCRB). Gudmundsson KS, Drach JC, Townsend LB ACS 1995 210 MEDI 098
2. 220436 Antiviral activity and mechanism of action of 1263W94, a benzimidazole riboside inhibitor of human cytomegalovirus. Biron KK, Davis MG, Stanat SC, Walton LM, Smith A, Koszalka GW, Drach JC, Townsend LB, Harvey RJ ICAAC 1996 36 Abs H85
3. 284474 In vivo anti-CMV activity and safety of oral 1263W94 in HIVinfected subjects with asymptomatic CMV shedding. Drew WL, Lalezari JP, Wang LH, Miner RC, Aberg JA, Wire MB INT CONF ANTIVIRAL RES 1998 11 Abs 110
4. 286280 Antiviral Research - 11th International Conference Herpesvirus Infections, San Diego, CA, USA. IDDB MEETING REPORT 1998 April 5-10
5. 287275 Interations of GW1263 with other antiviral agents in the inhibition of HCMV. Selleseth DW, Talarico CL, Lutz MW, Biron K, Miller T, Harvey J ICAAC 37 Abs H64
6. 287276 Activity against Epstein-Barr virus of benzimidazole riboside 126W94 (5,6-dichloro-2-(isopropylamino)-1-β-D-ribofuranosyl- 1H-benzimidazole). Zacny VL, Davis MG, Chamberlain SD, Townsend LB, Biron KK, Pagano JS ICAAC 1997 37 Abs H69
7. 288406 Design, synthesis and antiviral activity of α-nucleosides: D- and L-isomers of lyxofuranosyl- and (5- deoxylyxofuranosyl)benzimidazoles. Migawa MT, Girardet JL, Walker JA II, Koszalka GW, Chamberlain SD, Drach JC, Townsend LB J MED CHEM 1998 41 8 1242-1251
8. 319673 Comparison of the in vitro antiviral activities of 1263W94, ganciclovir, foscarnet and cidofovir for human cytomegalovirus (HCMV) clinical isolates as determined by flow cytometry and plaque reduction assays. McSharry J, Lurrain NS, Davis M, Talarico CL, Biron KK, Crumpacker CS ANTIVIRAL RES 1999 41 2 Abs 9
9. 354427 Glaxo Wellcome - product development pipeline February 2000. Glaxo Wellcome plc COMPANY BROCHURE 2000 February 01
10. 361067 1263W94 inhibits the phosphorylation of EBV DNA polymerase processivity factor BMRF1 by EBV protein kinase BGLF4. Gershburg E, Talarico C, Davis M, Sethna P, Pagano JS INT CONF ANTIVIRAL RES 2000 13 Abs 16
11. 372956 Synthesis and antiviral evaluation of halogenated β-D- and -L-erythrofuranosylbenzimidazoles. Gudmundsson KS, Tidwell J, Lippa N, Koszalka GW, van Draanen N, Ptak RG, Drach JC, Townsend LB J MED CHEM 2000 43 12 2464-2472
12. 381757 A phase I trial to evaluate the ocular (intravitreal) penetration of 1263W94 after multiple dose, oral administration in AIDS patients with CMV retinitis. Hendrix C, Kuppermann BD, Dunn JP, Wang LH, Starns E, Snowden BW, Hamzeh F, Wire MB ICAAC 2000 40 Abs 511
13. 388786 GlaxoWellcome - product development pipeline November 2000. Glaxo Wellcome plc COMPANY BROCHURE 2000 November 01
14. 399933 GSK phase II and III development pipeline. GlaxoSmithKline plc COMPANY COMMUNICATION 2001 February 23
15. 442449 Benzimidavir (1263W94) and subcellular localization of the EBV DNA processivity factor EA-D. Gershburg E, Pagano JS ANTIVIRAL RES 2002 53 3 Abs 53
16. 500710 ViroPharma licenses rights from GlaxoSmithKline for product candidate for cytomegalovirus (CMV) in immunocompromised patients. ViroPharma Inc PRESS RELEASE 2003 August 11
17. 500777 Phase I dose escalation trial evaluating the pharmacokinetics, anti-human cytomegalovirus (HCMV) activity, and safety of 1263W94 in human immunodeficiency virus-infected men with asymptomatic HCMV shedding. Lalezari JP, Aberg JA, Wang LH, Wire MB, Miner R, Snowden W, Talarico CL, Shaw S, Jacobson MA, Drew WL ANTIMICROB AGENTS CHEMOTHER 2002 46 9 2969-2976
18. 521193 ViroPharma initiates clinical program with maribavir for prevention of cytomegalovirus (CMV) infection in transplant patients. ViroPharma Inc PRESS RELEASE 2004 February 05
19. 532417 Interactions of 1263W94 with other antiviral agents in inhibition of human cytomegalovirus replication. Selleseth DW, Talarico CL, Miller T, Lutz MW, Biron KK, Harvey RJ ANTIMICROB AGENTS CHEMOTHER 2003 47 4 1468-1471
20. 532418 Resistance of human cytomegalovirus to the benzimidazole L-ribonucleoside maribavir maps to UL27. Komazin G, Ptak RG, Emmer BT, Townsend LB, Drach JC J VIROL 2003 77 21 11499-11506
21. 532421 In vitro activities of benzimidazole D- and L-ribonucleosides against herpesviruses. Williams SL, Hartline CB, Kushner NL, Harden EA, Bidanset DJ, Drach JC, Townsend LB, Underwood MR, Biron KK, Kern ER ANTIMICROB AGENTS CHEMOTHER 2003 47 7 2186-2192
22. 532422 Phase I safety and pharmacokinetic trials of 1263W94, a novel oral anti-human cytomegalovirus agent, in healthy and human immunodeficiency virus-infected subjects. Wang LH, Peck RW, Yin Y, Allanson J, Wiggs R, Wire MB ANTIMICROB AGENTS CHEMOTHER 2003 47 4 1334-1342
23. 532426 A new antiviral mechanism: Mutation of human cytomegalovirus gene UL27 confers resistance to the antiviral drug 1263W94. Komazin G, Ptak RG, Emmer BT, Evers DL, Townsend LB, Drach JC ANTIVIRAL RES 2003 57 3 A59
24. 532438 Preclinical and toxicology studies of 1263W94, a potent and selective inhibitor of human cytomegalovirus replication. Koszalka GW, Johnson NW, Good SS, Boyd L, Chamberlain SC, Townsend LB, Drach JC, Biron KK ANTIMICROB AGENTS CHEMOTHER 2002 46 8 2373-2380
25. 532439 Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole L-riboside with a unique mode of action. Biron KK, Harvey RJ, Chamberlain SC, Good SS, Smith AA 3rd, Davis MG, Talarico CL, Miller WH, Ferris R, Dornsife RE, Stanat SC et al ANTIMICROB AGENTS CHEMOTHER 2002 46 8 2365-2372
26. 532440 Phosphorylation of the Epstein-Barr virus (EBV) DNA polymerase processivity factor EA-D by the EBV-encoded protein kinase and effects of the L-riboside benzimidazole 1263W94. Gershburg E, Pagano JS J VIROL 2002 76 3 998-1003
27. 532441 Inhibition of ganciclovir-susceptible and -resistant human cytomegalovirus clinical isolates by the benzimidazole L-riboside 1263W94. McSharry JJ, McDonough A, Olson B, Talarico C, Davis M, Biron KK CLIN DIAGN LAB IMMUNOL 2001 8 6 1279-1281
28. 532444 The effect of benzimidazole nucleosides on human cytomegalovirus replication in the SCID-hu retinal and thymus/liver tissue implant models. Bidanset DJ, Rybak RJ, Collins DJ, Hartline CB, Drach JC, Townsend LB, Biron KK, Kern ER ANTIVIRAL RES 2001 501 A59
29. 532448 An efficient and scalable synthesis of the anti-HCMV agent 1263W94. Tidwell JH, Chamberlain SD, Hammitt R, Burns CL, Koszalka GW ACS 1998 216 2 ORGN 172
30. 532450 Synthesis and antiviral activity of several α-L- and α-Dlyxofuranosyl derivatives of 2-substituted 5,6-dichlorobenzimidazole nucleosides. Migawa MT, Girardet JL, Walker JA 3rd, Drach JC, Chamberlain SD, Koszalka GW, Townsend LB ACS 1997 214 1 MEDI 250
31. 532451 Synthesis and evaluation of a series of carbohydrate modified derivatives of the anti-HCMV agent, 5,6-dichloro-2-isopropylamino-1-(β-L- ribofuranosyl)-1H-benzimidazole (1263W94). Chamberlain SD, Chan JH, Tidwell JH, Peckham GE, Harvey RJ, Dornsife RE, Frick LW, Townsend LB, Drach JC, Koszalka GW ACS 1997 213 1 CARB 022
32. 547472 Cytomegalovirus infections. Garrett NW, Boeckh M CURR TREATMENT OPTIONS INFECT DISEASES 2001 3 78-91
33. 547481 Activities of benzimidazole D- and L-ribonucleosides in animal models of cytomegalovirus infections. Kern ER, Hartline CR, Rybak RJ, Drach JC, Townsend LB, Biron KK, Bidanset DJ ANTIMICROB AGENTS CHEMOTHER 2004 48 5 1749-1755
34. 547490 Cytomegalovirus. Taylor GH AM FAM PHYS 2003 67 3 519-524
35. 547493 Summary of the II International Symposium on Cytomegalovirus. de Jong MD, Galasso GJ, Gazzard B, Griffiths PD, Jabs DA, Kern ER, Spector SA ANTIVIRAL RES 1998 39 3 141-162
36. 547495 Cytomegalovirus infection in immunocompetent patients. Wreghitt TG, Teare EL, Sule O, Devi R, Rice P CLIN INFECT DIS 2003 37 12 1603-1606
37. 547498 Inhibition of influenza virus multiplication by N-glycosides of benzimidazoles-N. Tamm I, Folkers K, Shunk CH, Horsfall FL Jr J EXP MED 1954 99 3 227-250
38. 547499 Benzimidazole nucleosides, nucleotides, and related derivatives. Townsend LB, Revankar GR CHEM REV 1970 70 3 389-438
39. 547500 Design, synthesis, and antiviral activity of certain 2,5,6-trihalo-1-(β-D-ribofuranosyl)benzimidazoles. Townsend LB, Devivar RV, Turk SR, Nassiri MR, Drach JC J MED CHEM 1995 38 20 4098-4105
40. 547501 Synthesis and antiviral evaluation of certain disubstituted benzimidazole ribonucleosides. Zou R, Ayres KR, Drach JC, Townsend LB J MED CHEM 1996 39 18 3477-3482
41. 547503 Benzimidazoles for the treatment of human cytomegalovirus infection. Koszalka GW, Chamberlain SD, Harvey RJ, Frick LW, Good SS, Davis ML, Smith A, Drach JC, Townsend LB, Biron KK ANTIVIRAL RES 1996 30 Abs A43
42. 547532 Cytomegalovirus in immunocompromised persons. Schleiss MR CURR TREATMENT OPTIONS INFECT DISEASES 2002 4 43-45
43. 547582 The human cytomegalovirus UL97 protein kinase, an antiviral drug target, is required at the stage of nuclear egress. Krosky PM, Baek MC, Coen DM J VIROL 2002 77 2 905-914
44. 547583 Distinct and separate roles for herpesvirus-conserved UL97 kinase in cytomegalovirus DNA synthesis and encapsidation. Wolf DG, Courcelle CT, Prichard MN, Mocarski ES MICROBIOLOGY 2001 98 4 1895-1900
45. 547588 The human cytomegalovirus UL97 protein is a protein kinase that autophosphorylates on serines and threonines. He Z, He YS, Kim Y, Chu L, Ohmstede C, Biron KK, Coen DD J VIROL 1997 71 1 405-411
46. 547589 α-, β- and γ-Herpesviruses encode a putative phosphotransferase. Chee MS, Lawrence GL, Barrell BG J GEN VIROL 1989 70 5 1151-1160
47. 547591 Acyclovir is phosphorylated by the human cytomegalovirus UL97 protein. Talarico CL, Burnette TC, Miller WH, Smith SL, Davis MG, Stanat SC, Ng TI, He Z, Coen DM, Roizman B, Biron KK ANTIMICROB AGENTS CHEMOTHER 1999 43 8 1941-1946
48. 547596 A protein kinase homologue controls phosphorylation of ganciclovir in human cytomegalovirus-infected cells. Sullivan V, Talarico CL, Stanat SC, Davis M, Coen DM, Biron KK NATURE 1992 358 6382 162-164
49. 547598 A recombinant human cytomegalovirus with a large deletion in UL97 has a severe replication deficiency. Prichard MN, Gao N, Jairath S, Mulamba G, Krosky P, Coen DM, Parker BO, Pari GS J VIROL 1999 73 7 5663-5670
50. 547618 Development of novel benzimidazole riboside compounds for treatment of cytomegalovirus disease. Chulay J, Biron K, Wang L, Underwood M, Chamberlain S, Frick L, Good S, Davis M, Harvey R, Townsend L, Drach J, Koszalka G ADV EXP MED BIOL 1999 458 129-134.
51. 547634 Epstein-Barr viral latency is disrupted by the immediate-early BRLF1 protein through a cell-specific mechanism. Zalani S, Holley GE PROC NATL ACAD SCI USA 1996 93 17 9194-9199
52. 551087 ViroPharma Initiates Maribavir Phase 2 Program in Bone Marrow Transplant Patients. ViroPharma Inc PRESS RELEASE 2004 July 27